We develop, validate and implement clinical biomarker immunoassays through our high-complexity CLIA laboratory in the Boston area (licensed in all 50 States). We have expertise across a wide range of technology platforms and sample types.
ProterixBio offers a range of services to support the development and validation of protein biomarker assays. Our CLIA lab houses a highly experienced assay development team that can assist with the optimization of extraction procedures and the validation of analytical methods. Our team is flexible and efficient, and excels at adapting commercially available immunoassay reagent-systems to fit-for-purpose performance in target populations. We have experience across a wide range of therapeutic areas and a diverse range of sample types, including patient-centric samples such as dried blood spots.
We have also developed a Provider Portal and Testing Operations Software to meet your ordering, accessioning and reporting needs. We have built a cloud-based HIPAA compliant database solution that includes an API interface as well as an HL-7 engine for communicating with partners. Please contact us to discuss your Software needs.
We have the expertise to develop biomarker assays for remote sample collection, and implement the solution in a clinical context - from participant engagement through to data generation. Please contact us to discuss your project.
We also have extensive experience in the development of bioclinical tools to assess disease status in chronic obstructive pulmonary disease (COPD) and other chronic diseases. Learn more about our work.
ProterixBio maintains a rigorous approach to test development that includes collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts.Company Overview
We help develop, validate and implement tests that enable biotech or pharma companies to obtain high-quality protein biomarker data from remote sample collection.Our Platform
We perform the Critical Diagnostics Presage® ST2 Assay, which is indicated to be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.Our Test Menu
ProterixBio has developed a novel combination of blood-based biomarkers for identifying COPD populations at higher risk for severe exacerbation.Our Pipeline
Billerica, MA, February 8, 2023: ProterixBio, Inc. today announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA…Read More
Billerica, MA, November 17, 2021: ProterixBio, Inc. (CLIA: 22D2189261) today announced it has received a Clinical Laboratory Permit from New York State Department of Health. This permit enables ProterixBio to…Read More